Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes

Fecha de publicación: 01/06/2014

Autores de IIS La Fe

Alejandro Tormo Mico

Autor
Francisco Javier Celada Álvarez

Autor
Rafael Botella Estrada

Autor
Antonio Ballesta Cuñat

Autor
Maria Teresa Santos Diaz

Autor
José Pérez Calatayud

Autor

Participantes ajenos a IIS La Fe

Rodriguez S
Kasper M
Ouhib Z

Grupos

Dermatología y Regeneración Tisular

Leader

Rafael Botella Estrada

Abstract

Purpose: Radiotherapy (RT) has played a significant role in treating non melanoma skin cancer (NMSC). High-dose-rate brachytherapy (HDR-BT) approaches have a paramount relevance due to their adaptability, patient protection, and variable dose fractionation schedules. Several innovative applicators have been introduced to the brachytherapy community. The Valencia applicator is a new superficial device that improves the dose distribution compared with the Leipzig applicator. The purpose of this work is to assess the tumor control, cosmesis, and toxicity in patients with NMSC treated with the Valencia applicator and a new regimen of hypofractionation. Material and methods: From January 2008 to March 2010, 32 patients with 45 NMSC lesions were treated with the Valencia applicator in the Hospital La Fe. The gross tumor volume was visually assessed, but the tumor depth was evaluated using ultrasound imaging. All lesions for the selected cases were limited to 4 mm depth. The prescription dose was 42 Gy in 6 or 7 fractions (biologically effective dose [BED] approximate to 70 Gy), delivered twice a week. Results: Ninety-eight percent of the lesions were locally controlled at 47 months from treatment. Ninety-three percent of patients were out at least 36 months from treatment. The treatment was well tolerated in all cases. The highest skin toxicity was grade 1 RTOG/EORTC, having resolved with topical treatment at 4 weeks in all but one case which required 2 months. There were no grade 2 or higher late adverse events. Conclusions: In patients with superficial basal cell carcinoma lesions less than 25 mm in maximum diameter, HDRBT treatment with the Valencia applicator using a hypofractionated regimen provides excellent results, for both cosmetic and local control at a minimum of 3 years follow-up. Moreover, the shorter hypofractionated regimen facilitates compliance, which is very relevant for the elderly patients in our series. Valencia applicators offer a simple, safe, quick, and attractive nonsurgical treatment option.

Datos de la publicación

ISSN/ISSNe:: 1689-832X, 2081-2841
Tipo:: Article
Páginas:: 167-172
DOI:: 10.5114/jcb.2014.43247
Factor de Impacto:: 0,380 SCImago ℠
Cuartil:: Q3 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Tormo A:: Radiotherapy Department, La Fe University and Polytechnic Hospital, Valencia, Spain
Celada F:: Radiotherapy Department, La Fe University and Polytechnic Hospital, Valencia, Spain
Rodriguez S:: Radiotherapy Department, Benidorm Hospital, Alicante, Spain
Botella R:: Dermatology Department, La Fe University and Polytechnic Hospital, Valencia, Spain
Ballesta A:: Radiotherapy Department, La Fe University and Polytechnic Hospital, Valencia, Spain
Kasper M:: Radiation Oncology, Lynn Regional Cancer Center, Boca Raton, Florida, USA
Ouhib Z:: Radiation Oncology, Lynn Regional Cancer Center, Boca Raton, Florida, USA
Santos M:: Radiotherapy Department, Benidorm Hospital, Alicante, Spain
Perez-Calatayud J:: Physics Section, Department of Radiation Oncology, La Fe University Hospital, Valencia, Spain

Keywords

HDR; skin brachytherapy; skin cancer; Valencia applicators

Proyectos asociados

INVESTIGACION EN RED DE LAS ENFERMEDADES NEUROLOGICAS

Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA

C03/06 . INSTITUTO DE SALUD CARLOS III . 2003

AVANCES EN EL ESTUDIO DE LA REACTIVIDAD PLAQUETARIA Y SU INTERACCION CON LOS ERITROCITOS: BASES MOLECUALRES Y APLICABILIDAD CLINICO-FARMACOLOGICA

Investigador Principal: JUANA VALLES GINER

PI03/0270 . INSTITUTO DE SALUD CARLOS III . 2004

RED DE INVESTIGACION (RENEVAS)

Investigador Principal: ENRIQUE ALBORCH DOMÍNGUEZ

RD06/0026/0006 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS); FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006